.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
US Army
UBS
Cipla
Baxter
Healthtrust
QuintilesIMS
Chinese Patent Office
Chubb

Generated: December 13, 2017

DrugPatentWatch Database Preview

ULTRAM ER Drug Profile

« Back to Dashboard

When do Ultram Er patents expire, and what generic alternatives are available?

Ultram Er is a drug marketed by Valeant Pharms and is included in one NDA.

The generic ingredient in ULTRAM ER is tramadol hydrochloride. There are thirty-six drug master file entries for this compound. Sixty-six suppliers are listed for this compound. Additional details are available on the tramadol hydrochloride profile page.
Drug patent expirations by year for ULTRAM ER

Pharmacology for ULTRAM ER

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists

Medical Subject Heading (MeSH) Categories for ULTRAM ER

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Valeant PharmsULTRAM ERtramadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL021692-001Sep 8, 2005DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Valeant PharmsULTRAM ERtramadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL021692-002Sep 8, 2005DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Valeant PharmsULTRAM ERtramadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL021692-003Sep 8, 2005DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ULTRAM ER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant PharmsULTRAM ERtramadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL021692-001Sep 8, 2005► Subscribe► Subscribe
Valeant PharmsULTRAM ERtramadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL021692-003Sep 8, 2005► Subscribe► Subscribe
Valeant PharmsULTRAM ERtramadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL021692-002Sep 8, 2005► Subscribe► Subscribe
Valeant PharmsULTRAM ERtramadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL021692-003Sep 8, 2005► Subscribe► Subscribe
Valeant PharmsULTRAM ERtramadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL021692-002Sep 8, 2005► Subscribe► Subscribe
Valeant PharmsULTRAM ERtramadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL021692-001Sep 8, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ULTRAM ER

Drugname Dosage Strength RLD Submissiondate
tramadol hydrochlorideExtended-release Tablets300 mgUltram ER9/25/2007
tramadol hydrochlorideExtended-release Tablets200 mgUltram ER3/28/2007
tramadol hydrochlorideExtended-release Tablets100 mgUltram ER1/8/2007

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Cipla
Boehringer Ingelheim
Harvard Business School
Farmers Insurance
Deloitte
QuintilesIMS
Teva
Cantor Fitzgerald
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot